Original release date: November 12, 2021
Access to this course expires on: October 13, 2024 at 11:59 PM Pacific Time
The most recent (2016) WHO classification of hematologic neoplasms delineates specific diagnostic criteria for well-defined neoplastic entities. However, pathologists who diagnose bone marrow biopsies and lymphoid proliferations often face challenges that are not directly addressed by the WHO system or represent reactive conditions that may mimic hematologic malignancies. These include atypical morphologic features, unexpected immunostaining patterns, and discordant genetic features in neoplastic entities. Pathologists often have difficulties applying the WHO criteria if they are not fully concordant with the expected patterns and/or if they are relatively new entities with which pathologists may be unfamiliar. Moreover, there is inherent subjectivity in interpreting morphologic findings and even the results of ancillary testing. The literature contains reports about the intrinsic interobserver variability in making hematopathology diagnoses and pitfalls when applying established criteria. This course aims to bridge the practice gaps between the 'ideal world' WHO classification system and the 'real world' of hematopathology diagnosis by presenting challenging case examples. These cases will illustrate how to interpret correctly and apply morphologic criteria in diagnosing hematologic neoplasms (including newer entities), how to avoid diagnosing malignancy in benign mimics, and how appropriately to integrate the results of ancillary testing with the morphology, particularly when there are discordant or unexpected results. We will provide participants with guidelines on how practically to approach such cases and avoid misdiagnosis, thereby improving their performance in daily practice. The target audience is general pathologists who diagnose bone marrow and lymphoid lesions, practicing hematopathologists and hematopathology fellows.
Practicing academic and community pathologists, and pathologists-in-training
Upon completion of this educational activity, learners will be able to:
Continuing Medical Education
The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The United States and Canadian Academy of Pathology designates this enduring material for a maximum of 12.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to USCAP and to learners any financial relationship(s) that have occurred within the last 24 months with any commercial interest(s) whose products or services are related to the CME content. USCAP has reviewed all disclosures and mitigated all identified conflicts of interest, as applicable.
The following faculty reported no relevant financial relationships: Robert P. Hasserjian, MD, Adam Bagg, MD, Amy Chadburn, MD, Laurence de Leval, MD, PhD
The following IM Coordinator who planned and reviewed content for this activity reported no relevant financial relationships: Daniel Arber, MD
USCAP staff associated with the development of content for this activity reported no relevant financial relationships.
To earn CME credit, all learners must complete the evaluation. View and print your certificate by clicking here.
Buy the Course and get a great discount! Not A Member? Click Here